Seven‐Day Versus 14‐Day Tegoprazan and Tetracycline‐Containing Quadruple Therapy for First‐Line Eradication of Helicobacter pylori Infection: A Randomized, Open‐Label, Noninferiority Trial

医学 内科学 幽门螺杆菌 养生 胃肠病学 阿莫西林 随机对照试验 置信区间 四环素 意向治疗分析 不利影响 外科 抗生素 微生物学 生物
作者
Xueping Nan,Hongyu Zhao,Lei Guo,Rui‐Qi Zheng,Xi‐Lan Wang,Yong‐Fen Wang,Yan‐Hua Su,Wen‐Rong Geng,Xiu‐Lan Liu,Haimiao Xu,Ke‐Lun Zhou,Yuting Guo,Jian‐Hua Cao,Zhongxue Han,Qingzhou Kong,Xiu‐Li Zuo,Yanqing Li,Yue‐Yue Li
出处
期刊:Helicobacter [Wiley]
卷期号:30 (2): e70036-e70036 被引量:6
标识
DOI:10.1111/hel.70036
摘要

BACKGROUND AND AIMS: Tegoprazan, a new class of drugs, is a potassium-competitive acid blocker (P-CAB) that inhibits gastric H+/K+-ATPase through a different mechanism than proton pump inhibitor. Tetracycline also has anti-Helicobacter pylori properties. However, only a few randomized controlled trials (RCTs) have investigated the efficacy of tegoprazan and tetracycline-containing quadruple therapy (TTQT) for treating H. pylori infections, which this RCT explored. METHODS: This multicenter RCT included treatment-naïve adults with H. pylori infection who received 7 or 14 days of TTQT (50-mg tegoprazan, 220-mg bismuth potassium citrate, and 1000-mg amoxicillin twice daily with 500-mg tetracycline four times daily). The primary outcome was the eradication rate; secondary endpoints included the incidence of adverse events, treatment compliance, and regimen costs. RESULTS: The study included 258 patients. The eradication rates in the 7- and 14-day groups were 90.70% (117/129, 95% confidence interval [CI]: 83.98%-94.89%) and 91.47% (118/129, 95% CI: 84.90%-95.45%), respectively, in the intention-to-treat analysis (difference: -0.78%; -7.01%-8.58%; noninferiority p < 0.001); 92.86% (117/126, 95% CI: 86.50%-96.48%) and 93.65% (118/126, 95% CI: 87.47%-97.02%), respectively, in the modified intention-to-treat analysis (difference: 0.79%; 95% CI: -6.36%-7.99%; noninferiority p < 0.001); and 94.35% (117/124, 95% CI: 88.29%-97.50%) and 95.12% (117/123, 95% CI: 89.24%-98.00%), respectively, in the per-protocol analysis (difference: -0.77%; 95% CI: -5.91%-7.48%; noninferiority p < 0.001). Significantly fewer adverse events occurred in the 7-day group than in the 14-day group (22.48% vs. 35.67%, p = 0.020). Treatment compliance did not differ between the two groups. CONCLUSIONS: The 7- and 14-day TTQT efficacies for the first-line treatment of H. pylori infection were comparable, and fewer adverse effects occurred in the 7-day group. This trial has been registered at Clinical Trials.gov (NCT05997433).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
余谏己完成签到 ,获得积分10
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
天天向上的应助被科研通管家采纳,获得30
1秒前
1秒前
Jasper的应助被科研通管家采纳,获得30
1秒前
上官若男的应助被科研通管家采纳,获得10
1秒前
赘婿的应助被科研通管家采纳,获得10
1秒前
Akim的应助被pinguin采纳,获得10
1秒前
JamesPei的应助被科研通管家采纳,获得10
1秒前
DW的应助被科研通管家采纳,获得10
1秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
2秒前
leecopper001发布了新的文献求助10
2秒前
搜集达人的应助被科研通管家采纳,获得10
2秒前
小二郎的应助被科研通管家采纳,获得10
2秒前
ding的应助被科研通管家采纳,获得10
2秒前
why发布了新的文献求助10
2秒前
orixero的应助被科研通管家采纳,获得10
2秒前
上官若男的应助被科研通管家采纳,获得10
2秒前
2秒前
华仔的应助被科研通管家采纳,获得30
2秒前
李68发布了新的文献求助10
2秒前
在望的应助被科研通管家采纳,获得10
3秒前
fantasy的应助被科研通管家采纳,获得10
3秒前
molihuakai的应助被科研通管家采纳,获得10
3秒前
3秒前
风吹麦浪发布了新的文献求助10
3秒前
大个的应助被科研通管家采纳,获得10
3秒前
3秒前
Orange的应助被科研通管家采纳,获得10
3秒前
风吹麦浪发布了新的文献求助10
3秒前
3秒前
酷波er的应助被科研通管家采纳,获得10
3秒前
3秒前
NexusExplorer的应助被科研通管家采纳,获得10
3秒前
领导范儿的应助被科研通管家采纳,获得10
3秒前
bkagyin的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186676
求助须知:如何正确求助?哪些是违规求助? 9574945
关于积分的说明 21839037
捐赠科研通 7784275
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559187
邀请新用户注册赠送积分活动 2481611